Beijing (AFP) — A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.
The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.
A drug being tested by scientists at China’s prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.
Fingerprints and DNA are widely known forms of biometrics, thanks to crime dramas on television. But as technology advances the Internet of Things, the interconnection of computer devices in common objects, other forms of biometrics are sought for security. For example, distinctive physical characteristics of users are increasingly used in computer science as forms of identification and access restriction. Smartphones use fingerprints, iris scans and face recognition in this way. Other biometrics that are likely to come into use include retinas, veins and palm prints.
The ear is another potential biometric. According to research published recently in the Journal of Electronic Imaging, ear recognition technology, or “earprints,” could one day be used as personal identification to secure smart homes via smartphones.
A pre-print study reveals that young blood plasma given to older mice reduced aging by an average of 54% across multiple tissues; and had an impact on other signs of aging, such as cellular senescence, fat accumulation, and behavioural measures.
A Duke University research team has found a small area of the brain in mice that can profoundly control the animals’ sense of pain.
Somewhat unexpectedly, this brain center turns pain off, not on. It’s also located in an area where few people would have thought to look for an anti-pain center, the amygdala, which is often considered the home of negative emotions and responses, like the fight or flight response and general anxiety.
“People do believe there is a central place to relieve pain, that’s why placebos work,” said senior author Fan Wang, the Morris N. Broad Distinguished Professor of neurobiology in the School of Medicine. “The question is where in the brain is the center that can turn off pain.”
U.S. National Institute of Allergy and Infectious Diseases Director Anthony Fauci called the vaccine’s preclinical data “impressive” and told National Geographic this week that a vaccine could be ready for general use as early as January.
The Phase I trial has dosed 45 healthy adults. Phase II trials are about to start, enrolling around 600 adults. Pivotal efficacy trials would follow soon thereafter, bankrolled in collaboration with the government office BARDA (Biomedical Advanced Research and Development Authority).
Today, the chief medical officer of Moderna, Tal Zaks, answered burning questions from the public in a webinar hosted by STAT. Here’s an edited and condensed summary of his answers.
The coronavirus is spreading rapidly throughout Brazil, overwhelming a health care system that is ill prepared to handle a pandemic of this magnitude and proving especially deadly for the medical workers on the front lines.
At least 116 nurses have died in this country of 210 million from Covid-19, according to Brazil’s Federal Nursing Council—the highest toll anywhere. That is more than the 107 nurses who have died in the U.S., where the total death count of people succumbing to the pandemic is about six times more than in Brazil. In Italy, which has about twice as many total deaths as Brazil, 39 nurses have died, according to Italy’s National Federation of Nurses, or Fnopi.
Chinese President Xi Jinping pledged to make any coronavirus vaccine universally available once it’s developed, part of an effort to defuse criticism of his government’s response to a pandemic that has killed more than 315,000 people around the world.
In a speech on Monday to the World Health Assembly, the governing body of the Geneva-based World Health Organization, Xi called for greater international cooperation in fighting the pandemic. He also said China will provide $2 billion over two years to support the fight. Taiwan dropped a request to be included in the gathering after objections from Beijing.
Using CRISPR, Sandia National Lab researchers are genetically engineering antiviral countermeasures to fight the coronavirus—and potentially future outbreaks.
Circa 2018
Two articles recently described the development of CRISPR technologies that have the potential to fundamentally transform the barcoding and tracing of mammalian cells.
The results of a clinical trial released today (May 18, 2020) in STEM CELLS Translational Medicine demonstrate how a topical solution made up of stem cells leads to the regrowth of hair for people with a common type of baldness.
Androgenetic alopecia (AGA) — commonly known as male-pattern baldness (female-pattern baldness in women) — is a condition caused by genetic, hormonal and environmental factors. It affects an estimated 50 percent of all men and almost as many women older than 50. While it is not a life-threatening condition, AGA can lower a person’s self-esteem and psychological well-being. There are a few FDA-approved medications to treat hair loss, but the most effective can have side effects such as loss of libido and erectile dysfunction. Therefore, the search continues for a safer, effective treatment.
Adipose tissue-derived stem cells (ADSCs) secrete several growth hormones that help cells develop and proliferate. According to laboratory and experimental studies, growth factors such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF) and platelet-derived growth factor (PDGF) increase the size of the hair follicle during hair development.